We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+16.4%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$6.8B
AUM Growth
+$1.2B
Cap. Flow
+$636M
Cap. Flow %
9.34%
Top 10 Hldgs %
38.38%
Holding
154
New
24
Increased
52
Reduced
26
Closed
34

Top Buys

Rank Stock Value
1
RLYP
RELYPSA INC COM
RLYP
+$204M
2
PRGO icon
Perrigo
PRGO
+$111M
3
ABBV icon
AbbVie
ABBV
+$99.2M
4
CELG
Celgene Corp
CELG
+$71.2M
5
ZBH icon
Zimmer Biomet
ZBH
+$70.4M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$169M
2
ELV icon
Elevance Health
ELV
+$69M
3
WCRX
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
+$56.2M
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$53.1M
5
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$52.7M

Sector Composition

Rank Sector Weight
1 Healthcare 85.54%
2 Miscellaneous 13.17%
3 Financials 1.18%
4 Technology 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CPRX
101
DELISTED
Catalyst Pharmaceutical
CPRX
$3.69M 0.05%
1,895,000
– –
INCY icon
102
CALL
Incyte
INCY
$24.8B
$3.54M 0.05%
+70,000
New +$3.05M
HSP
103
DELISTED
HOSPIRA INC
HSP
$3.51M 0.05%
+85,000
New +$3.42M
ACAD icon
104
Acadia Pharmaceuticals
ACAD
$4.74B
$3.37M 0.05%
135,000
-177,000
-57% -$4.18M
BLRX
105
BioLineRX
BLRX
$12.2M
$3.19M 0.05%
1,892
-333
-15% -$537K
ANTH
106
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$2.86M 0.04%
116,594
– –
QLTI
107
DELISTED
QLT Inc
QLTI
$2.51M 0.04%
450,000
-150,000
-25% -$743K
XTNT icon
108
Xtant Medical Holdings
XTNT
$46M
$1.63M 0.02%
27,120
+12,500
+85% +$799K
ALBO
109
DELISTED
Albireo Pharma Inc
ALBO
$1.25M 0.02%
18,248
-11,667
-39% -$855K
AMRN
110
Amarin Corp
AMRN
$291M
$1.18M 0.02%
30,000
– –
ISEE
111
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.12M 0.02%
+34,500
New +$1.02M
EXAS
112
PUT
DELISTED
Exact Sciences
EXAS
$1.01M 0.01%
+86,200
New +$989K
CHDX
113
DELISTED
CHINDEX INTL INC
CHDX
$627K 0.01%
36,000
+4,000
+13% +$65.9K
SPY icon
114
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$803B
$370K 0.01%
250,000
+50,000
+25% +$8.85M
TEVA icon
115
PUT
Teva Pharmaceuticals
TEVA
$45.1B
$152K ﹤0.01%
200,000
-100,000
-33% -$3.94M
A icon
116
CALL
Agilent Technologies
A
$41.4B
– –
-419,400
Closed -$15.4M
ALGN icon
117
Align Technology
ALGN
$10.9B
– –
-766,000
Closed -$36.8M
BLUE
118
DELISTED
bluebird bio
BLUE
– –
-17,177
Closed -$6M
BSX icon
119
Boston Scientific
BSX
$65.3B
– –
-170,000
Closed -$2M
CI icon
120
Cigna
CI
$74.2B
– –
-438,000
Closed -$33.7M
CNC icon
121
Centene
CNC
$34.3B
– –
-1,673,200
Closed -$26.8M
CYH icon
122
Community Health Systems
CYH
$412M
– –
-329,120
Closed -$11.3M
DVAX
123
DELISTED
Dynavax Technologies
DVAX
– –
-898,600
Closed -$10.7M
ESPR
124
DELISTED
Esperion Therapeutics
ESPR
– –
-60,800
Closed -$1.15M
EW icon
125
Edwards Lifesciences
EW
$49.3B
– –
-300,000
Closed -$3.48M
2 3 4
5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q4 2013 Portfolio in Review

As of Q4 2013, OrbiMed held 154 positions worth $6.8B, up 21% from $5.6B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed deployed $636M of net new capital in Q4 2013, opening 24 new positions and adding to 52 existing holdings. Its largest new stake was RELYPSA INC COM: 9,941,549 shares worth $249M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Merck, an estimated $169M trimmed.

  • OrbiMed's largest Q4 2013 buy was RELYPSA INC COM: 9,941,549 shares worth $249M.
  • OrbiMed added most to AbbVie in Q4 2013, an estimated $99.2M increase.
  • OrbiMed's biggest Q4 2013 reduction was Merck, cutting an estimated $169M.
  • OrbiMed fully exited WARNER CHILCOTT PLC ORD SHS CL A (IRL) in Q4 2013, selling an estimated $56.2M.
  • OrbiMed's ten largest holdings make up 38% of its $6.8B portfolio in Q4 2013.
  • OrbiMed opened 24 new positions and closed 34 in Q4 2013.
  • OrbiMed's portfolio value rose 21% quarter-over-quarter to $6.8B.

Based on OrbiMed's 13F filing for Q4 2013, filed 14 Feb 2014.